BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29074604)

  • 1. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.
    Byron SA; Tran NL; Halperin RF; Phillips JJ; Kuhn JG; de Groot JF; Colman H; Ligon KL; Wen PY; Cloughesy TF; Mellinghoff IK; Butowski NA; Taylor JW; Clarke JL; Chang SM; Berger MS; Molinaro AM; Maggiora GM; Peng S; Nasser S; Liang WS; Trent JM; Berens ME; Carpten JD; Craig DW; Prados MD
    Clin Cancer Res; 2018 Jan; 24(2):295-305. PubMed ID: 29074604
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 4. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
    Farrell C; Shi W; Bodman A; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal analysis of treatment-induced genomic alterations in gliomas.
    Erson-Omay EZ; Henegariu O; Omay SB; Harmancı AS; Youngblood MW; Mishra-Gorur K; Li J; Özduman K; Carrión-Grant G; Clark VE; Çağlar C; Bakırcıoğlu M; Pamir MN; Tabar V; Vortmeyer AO; Bilguvar K; Yasuno K; DeAngelis LM; Baehring JM; Moliterno J; Günel M
    Genome Med; 2017 Feb; 9(1):12. PubMed ID: 28153049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
    Rahman R; Trippa L; Alden S; Fell G; Abbasi T; Mundkur Y; Singh NK; Talawdekar A; Husain Z; Vali S; Ligon KL; Wen PY; Alexander BM
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):716-724. PubMed ID: 32417407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
    Pfaff E; Kessler T; Balasubramanian GP; Berberich A; Schrimpf D; Wick A; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Capper D; Schenkel I; Eisenmenger A; Dettmer S; Brors B; Platten M; Pfister SM; von Deimling A; Jones DTW; Wick W; Sahm F
    Neuro Oncol; 2018 May; 20(6):826-837. PubMed ID: 29165638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
    Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
    Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
    Lau D; Magill ST; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.
    Aung KL; Fischer SE; Denroche RE; Jang GH; Dodd A; Creighton S; Southwood B; Liang SB; Chadwick D; Zhang A; O'Kane GM; Albaba H; Moura S; Grant RC; Miller JK; Mbabaali F; Pasternack D; Lungu IM; Bartlett JMS; Ghai S; Lemire M; Holter S; Connor AA; Moffitt RA; Yeh JJ; Timms L; Krzyzanowski PM; Dhani N; Hedley D; Notta F; Wilson JM; Moore MJ; Gallinger S; Knox JJ
    Clin Cancer Res; 2018 Mar; 24(6):1344-1354. PubMed ID: 29288237
    [No Abstract]   [Full Text] [Related]  

  • 11. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
    Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
    Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial.
    Bonneville-Levard A; Frappaz D; Tredan O; Lavergne E; Corset V; Agrapart V; Chabaud S; Pissaloux D; Wang Q; Attignon V; Cartalat S; Ducray F; Thomas-Maisonneuve L; Honnorat J; Meyronet D; Taillandier L; Blonski M; Viari A; Baudet C; Sohier E; Lantuejoul S; Paindavoine S; Treilleux I; Rodriguez C; Pérol D; Blay JY
    Med Oncol; 2021 Nov; 39(1):4. PubMed ID: 34739635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study.
    van Opijnen MP; Broekman MLD; de Vos FYF; Cuppen E; van der Hoeven JJM; van Linde ME; Compter A; Beerepoot LV; van den Bent MJ; Vos MJ; Fiebrich HB; Koekkoek JAF; Hoeben A; Kho KH; Driessen CML; Jeltema HR; Robe PAJT; Maas SLN
    BMC Med Genomics; 2022 Nov; 15(1):233. PubMed ID: 36333718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing.
    Virk SM; Gibson RM; Quinones-Mateu ME; Barnholtz-Sloan JS
    PLoS One; 2015; 10(5):e0124178. PubMed ID: 25950952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
    Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
    Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.
    Weiss GJ; Byron SA; Aldrich J; Sangal A; Barilla H; Kiefer JA; Carpten JD; Craig DW; Whitsett TG
    PLoS One; 2017; 12(6):e0179170. PubMed ID: 28586388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studying a complex tumor: potential and pitfalls.
    Zheng S; Chheda MG; Verhaak RG
    Cancer J; 2012; 18(1):107-14. PubMed ID: 22290264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive profile of recurrent glioblastoma.
    Campos B; Olsen LR; Urup T; Poulsen HS
    Oncogene; 2016 Nov; 35(45):5819-5825. PubMed ID: 27041580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
    Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
    Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.
    Lowery MA; Jordan EJ; Basturk O; Ptashkin RN; Zehir A; Berger MF; Leach T; Herbst B; Askan G; Maynard H; Glassman D; Covington C; Schultz N; Abou-Alfa GK; Harding JJ; Klimstra DS; Hechtman JF; Hyman DM; Allen PJ; Jarnagin WR; Balachandran VP; Varghese AM; Schattner MA; Yu KH; Saltz LB; Solit DB; Iacobuzio-Donahue CA; Leach SD; O'Reilly EM
    Clin Cancer Res; 2017 Oct; 23(20):6094-6100. PubMed ID: 28754816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.